Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium

Respiratory Medicine

Volumn 106, Issue 12, 2012, Pages 1722-1733

  Hettle, Robert ^a   Wouters, Hanne ^b   Ayres, Jon ^c   Gani, Ray ^d   Kelly, Steve ^e   Lion, Michaela ^a   Decramer, Marc ^f  

^a Heron Evidence Development Ltd   (United Kingdom)

^b Pricing and Outcomes Research   (Belgium)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BOEHRINGER INGELHEIM LTD   (United Kingdom)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

COPD; Cost utility; Economic; Tiotropium

Indexed keywords

TIOTROPIUM BROMIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BELGIUM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; INTERMETHOD COMPARISON; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT OUTCOME; UNITED KINGDOM;

BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867741217     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.09.006     Document Type: Article

References (28)

1. The National Health Service Information Centre. Quality and outcomes framework: achievement and prevalence bulletin 2010/2011. http://www ic nhs uk/statistics-and-data-collections/supporting-information/audits-and- performance/the-quality-and-outcomes-framework/qof-2010-11/qof-2010-11-bulletin 2011.
2. R. Hooper, P. Burney, W.M. Vollmer, M.A. McBurnie, T. Gislason, and W.C. Tan Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project Eur Respir J 39 6 2012 Jun 1343 1353
3. Scientific Institute for Public Health Health interview survey 2008 Scientific Institute for Public Health Available from: URL: http://www.iph.fgov. be
4. GOLD Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2011
5. NICE guideline. NICE. CG12 chronic obstructive pulmonary disease. http://www nice org uk/nicemedia/pdf/CG012-niceguideline pdf 2004.
6. R.G. Barr, J. Bourbeau, C.A. Camargo, and F.S. Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax 61 10 2006 Oct 854 862
7. J.A. Mauskopf, C.L. Baker, B.U. Monz, and M.D. Juniper Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence J Med Econ 13 3 2010 Sep 403 417
8. J.B. Oostenbrink, M.J. Al, M. Oppe, and M.P. Rutten-van Molken Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research Value Health 11 7 2008 Dec 1070 1080
9. M.P. Rutten-van Molken, J.B. Oostenbrink, M. Miravitlles, and B.U. Monz Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Eur J Health Econ 8 2 2007 Jun 123 135
10. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 15 2008 Oct 9 1543 1554
11. I. Cleemput, P. Van Wilder, F. Vrijens, M. Huybrechts, and D. Ramaekers Guidelines for pharmacoeconomic evaluations in Belgium. Health technology assessment (HTA) 2008 Health Care Knowledge Centre (KCE) Brussels KCE Reports 78C
12. R. Gani, J. Griffin, S. Kelly, and M.M. Rutten-van Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Prim Care Respir J 19 1 2010 Mar 68 74
13. W. Schramm, D. Haake, and A. Brandt Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease Praxis 94 46 2005 Nov 16 1803 1810
14. N. Maniadakis, N. Tzanakis, V. Fragoulakis, M. Hatzikou, and N. Siafakas Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece Curr Med Res Opin 22 8 2006 Aug 1599 1607
15. J.B. Oostenbrink, M.P. Rutten-van Molken, B.U. Monz, and J.M. FitzGerald Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries Value Health 8 1 2005 Jan 32 46
16. J.B. Oostenbrink, M.P. Rutten-van Molken, M.J. Al, J.A. Van Noord, and W. Vincken One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Eur Respir J 23 2 2004 Feb 241 249
17. National Clinical Guideline Centre Chronic obstructive pulmonary disease: management of adults with chronic obstructive pulmonary disease in primary and secondary care. Update guideline 2009 Report No.: Version 03.11.09 13:30
18. C.H. Jackson, L.D. Sharples, S.G. Thompson, S.W. Duffy, and E. Couto Multistate Markov models for disease progression with classification error The Statistician 52 2003 193 209
19. C.H. Jackson Multi-state modelling with R: the msm package Version 0.9.6. Available from: URL: 2010 http://www stats bris ac uk/R/web/packages/msm/index html http://www.stats.bris.ac.uk/R/web/packages/msm/index.html
20. Version R: a language and environment for statistical computing [computer program] 2008 3-900051-07-0
21. The EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life Health Policy 16 3 1990 199 208
22. M.P. Rutten-van Molken, J.B. Oostenbrink, D.P. Tashkin, D. Burkhart, and B.U. Monz Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 130 4 2006 Oct 1117 1128
23. I. Cleemput A social preference valuations set for EQ-5D health states in Flanders Belgium Eur J Health Econ 11 2 2010 Apr 205 213
24. P. Dolan, G. Gudex, P. Kind, and A. Williams A social tariff for EuroQol: results from a UK general population survey 1995 Centre for Health Economics, University of York
25. MIMS. MIMS online. http://www healthcarerepublic com/mims/2009.
26. L. Bodson, J. Grenade, J. Micheels, and V. D'Orio The value of mobile intensive care unit (MICU): does it remain to be proven? Rev Med Liege 61 5-6 2006 May 494 499
27. M. Neyt, S. Devriese, N. Thiry, and B.A. Van den Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions BMC Pulm Med 10 2010 47
28. M. Neyt, A. Van den Bruel, J. Gailly, N. Thiry, and S. Devriese Tiotropium in the treatment of chronic obstructive pulmonary disease: health technology assessment 2009 KCE report 108C